Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 March 2024 | Story Anthony Mthembu | Photo Lutendo Mabata
Prof Nompumelelo Zondi
Prof Nompumelelo Zondi, the newly appointed Vice-Dean: Research and Postgraduate Studies in the Faculty of The Humanities at the University of the Free State (UFS).

Prof Nompumelelo Zondi has been appointed as Vice-Dean: Research and Postgraduate Studies in the Faculty of The Humanities at the University of the Free State (UFS). Prof Zondi assumed this new role on 1 March 2024 after serving as the Head of Department for African Languages at the University of Pretoria for seven years. “I consider this appointment as an opportunity of growth and learning more about higher education and the Faculty of The Humanities at large,” she said.

Prof Zondi indicates that part of her role is to spearhead the UFS Vision130 within the Faculty of The Humanities, and to ensure that the faculty assists the institution in becoming research-led, student-centred, and globally impactful. 

Motivation for assuming this role

One of the primary reasons that led her to consider this role is sharing the knowledge she acquired as part of the Fulbright South African Research Scholar Programme. As a result of that experience and exposure, which went beyond the Ohio State University, she felt it befitting to implement some of the insights she acquired on a bigger scale. Therefore, even though she was impactful in her previous role, Prof Zondi believes that this is an exceptional and more desirable platform to do so. “I feel that I will have easier access to departments within the faculty, while also encouraging and supporting interdepartmental and faculty collaborations,” she explained.

A significant component of Vision 130

He believes that the elements that make up Vision 130 are interrelated. While she considers research central to Vision 130 – as she begins her journey at the UFS, she feels students deserve to be nurtured to further contribute to the university’s impactful research. Thus, student-centredness is the way to go. “I believe that students must be major role players in this Vision130; we must include them in the interactions and discussions that are part of the university’s strategic plan as well as in decision-making processes,” she said. As such, according to Prof Zondi, the more the faculty and the institution care for the students and involve them in Vision130 and in collaborations, the more research outputs the university will achieve. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept